We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
45 result(s) found, displaying 1 to 10
-
-
Australian public assessment report (AusPar)Lamzede (velmanase alfa) has been approved as an enzyme replacement therapy for the treatment of non-central nervous system manifestations in patients with alpha-mannosidosis.
-
Sep-2025Prescription medicine evaluationActive ingredient: metreleptin.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ELFABRIO pegunigalsidase alfa 20 mg/10 mL concentrated injection vial.
-
Cancellation by sponsorRequested by Chiesi Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAMZEDE velmanase alfa 10 mg powder for injection vial.
-
-
Prescription medicine registrationActive ingredients: pegunigalsidase alfa.
-
Apr-2025Prescription medicine evaluationActive ingredient: birch bark dry extract (84-95 per cent) triterpenes.
-
Prescription medicine registrationActive ingredients: velmanase alfa.